<DOC>
	<DOCNO>NCT00428454</DOCNO>
	<brief_summary>Primary intracoronary stent placement successfully cross chronic total coronary occlusion ( CTO ) decrease high restenosis rate long-term follow-up compare conventional balloon angioplasty . Several study show efficacy sirolimus-eluting stent select group patient . In PRISON II study demonstrate sirolimus-eluting stent superior bare metal stent CTO . In prospective randomize trial , sirolimus-stent implantation compare zotarolimus-eluting stent implantation treatment chronic total coronary occlusion . A total 300 patient clinically follow 1 , 6 , 12 month , 2 , 3 , 4 , 5 year angiographic follow-up 8 month . Quantitative coronary analysis perform independent core laboratory . The primary end point in-segment late luminal loss 8 month angiographic follow-up .</brief_summary>
	<brief_title>Sirolimus-eluting v Zotarolimus-eluting Stents Chronic Total Coronary Occlusions</brief_title>
	<detailed_description>Percutaneous coronary intervention ( PCI ) chronic total occlusion ( CTO ) traditionally limited high restenosis rate . Coronary stenting use bare metal stent significantly decrease restenosis CTO compare balloon angioplasty alone , restenosis rate still reach 32-55 % . In 200 patient CTO , randomize PRISON I study demonstrated restenosis rate 22 % bare metal stent ( BMS ) implantation compare 33 % conventional balloon angioplasty . During past year , sirolimus ( rapamycin ) , cytostatic macrocyclic lactone anti-inflammatory antiproliferative property , deliver polymer-encapsulated stent show almost eliminate risk restenosis select group patient . The drug zotarolimus ( ABT-578 ) , sirolimus analogue , design inhibit cellular process lead restenosis . In PRISON II study randomize 200 patient CTO either BMS implantation sirolimus-eluting stent implantation demonstrate reduction in-stent binary restenosis 36 % 7 % in-segment binary restenosis rate 41 % 11 % favour sirolimus elute stent . However , data available direct comparison clinical efficacy , safety , angiographic outcome particular drug-eluting stent patient CTO may differences various drug-eluting stent . The PRISON III study design address issue provide information two different drug-eluting stent . It prospective randomize , single blind trial compare relative safety , clinical efficacy angiographic outcome sirolimus zotarolimus-eluting stent patient undergo successful recanalization CTO .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>INCLUSION CRITERIA estimate duration occlusion least 2 week . sign ischemia relate occlude coronary artery . successful recanalization occlude artery achieve . reference diameter &gt; 2.5 mm . write informed consent obtain . EXCLUSION CRITERIA primary rescue PCI acute myocardial infarction lesion could cross . lesion complex anatomy make successful stent deployment unlikely . guide wire true lumen distal occlusion . Sirolimus zotarolimus allergy venous arterial bypass graft pregnant nursing woman . participation trial . factor make longterm followup difficult unlikely . life expectancy &lt; 1 year . contraindication ASA Clopidogrel heparin . use coumadin could stop procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>chronic total occlusion</keyword>
	<keyword>sirolimus-eluting stent</keyword>
	<keyword>zotarolimus-eluting stent</keyword>
	<keyword>QCA</keyword>
</DOC>